Certain exclusivity rights protect Kazano (alogliptin and metformin) from being made into a generic product. After these rights expire in March 2025, companies may be allowed to make generic versions of Kazano. However, if lawsuits or patents are filed for new uses of the drug, it may delay the product's availability.
Kazano® (alogliptin and metformin) is a prescription medication used to treat adults with type 2 diabetes. It contains a combination of two diabetes medicines: metformin (Glucophage®) and alogliptin (Nesina®).
Kazano is made by Takeda Pharmaceuticals America, Inc. It is currently protected from generic competition by exclusivity rights that have not yet expired.
Takeda holds the exclusive rights to market Kazano in the United States until at least March 2025. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This includes such things as lawsuits or other patents for new Kazano uses. Once the exclusivity rights expire, there may be several companies that manufacture a generic Kazano drug.
No -- metformin and alogliptin are the active ingredients in Kazano, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.